ITeos Therapeutics Operating Income

As of the most recent data (June 2025), ITOS shows a operating income of $-220M. That compares with $-140M in the prior-year period — down 53.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ITOS's operating income is now $-220M (was $-140M) — a 53.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether ITeos Therapeutics is outperforming or lagging.

Tracking ITOS's operating income over time shows whether ITeos Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-220M That compares with $-140M in the prior-year period — down 53.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has ITeos Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-220M) with ownership activity and broader fundamentals.

ITeos Therapeutics's operating income is $-220M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.